Nina Powell, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: N5367 Mayflower Rd, Shiocton, WI 54170 Phone: 920-986-3003 Fax: 920-986-3004 |
Mrs. Tracy L Wilke Kohlman, APSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: N5367 Mayflower Rd, Shiocton, WI 54170 Phone: 920-738-7795 Fax: 920-986-3004 |
Mrs. Lynn Elizabeth Martin Mulvey, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: N5367 Mayflower Rd, Shiocton, WI 54170 Phone: 920-986-3003 Fax: 920-986-3004 |
News Archive
StockPreacher.com announces an investment report featuring CardioNet, Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The first study to use cutting edge magnetic resonance imaging to examine the effect of a statin - rosuvastatin (Crestor) - on the fatty plaques in arteries, was presented yesterday at the 75th European Atherosclerosis Society Congress. ORION revealed that rosuvastatin has a beneficial effect on the size and composition of fatty plaques in arteries (specifically the carotid artery in the neck). Fatty plaques that are vulnerable to sudden rupture can cause heart attacks and strokes without warning.
Performing a repeat surgery for patients with peritonitis (severe intra-abdominal inflammation or infection) only when clinical improvement is lacking may have some advantages compared with having the repeat procedure routinely scheduled after the operation, according to a study in the August 22/29 issue of JAMA.
Zassi Medical Evolutions, a privately held organization that innovates, designs and develops high technology medical devices and software announced today that it has successfully spun out and formed a new company with Tucson, Arizona based Research Corporation Technologies (RCT) to pursue the continued development of a novel electrical stimulation technology for the gastrointestinal continence control market.
As acknowledged in the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19 recently published in Lancet (Wang, et al., April 29, 2020), a statistician at Rutgers Cancer Institute of New Jersey was called on to guard the integrity of that trial.
› Verified 9 days ago